International, expanded access program of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy (VEGFr-TKI): Subanalysis from emerging growth market (EGM) countries | AVESİS

Gazi Üniversitesi Akademik Veri Yönetim Sistemi

International, expanded access program of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy (VEGFr-TKI): Subanalysis from emerging growth market (EGM) countries

Atıf İçin Kopyala

Lee S., Buyukberber S., Ou Y., Shapiro J. D. , Panneerselvam A., Arikan O. O. , ...Daha Fazla

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30

Cilt numarası: 30
Basıldığı Şehir: Illinois
Basıldığı Ülke: Amerika Birleşik Devletleri